Pfizer Inc. (NYSE:PFE) Shares Sold by Park National Corp OH

Park National Corp OH lessened its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 29.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 59,551 shares of the biopharmaceutical company's stock after selling 24,741 shares during the period. Park National Corp OH's holdings in Pfizer were worth $1,509,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of PFE. Tallon Kerry Patrick purchased a new position in shares of Pfizer during the fourth quarter worth about $509,000. Brighton Jones LLC grew its holdings in shares of Pfizer by 1,282.4% during the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock worth $17,677,000 after buying an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC grew its holdings in shares of Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock worth $498,000 after buying an additional 2,087 shares during the last quarter. Asset Dedication LLC grew its holdings in shares of Pfizer by 107.4% during the fourth quarter. Asset Dedication LLC now owns 26,833 shares of the biopharmaceutical company's stock worth $712,000 after buying an additional 13,896 shares during the last quarter. Finally, Strategic Blueprint LLC grew its holdings in shares of Pfizer by 2.0% during the fourth quarter. Strategic Blueprint LLC now owns 47,169 shares of the biopharmaceutical company's stock worth $1,251,000 after buying an additional 942 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Price Performance

Shares of PFE stock traded up $0.01 during midday trading on Friday, reaching $23.46. 56,576,195 shares of the company traded hands, compared to its average volume of 41,238,982. The firm's 50 day simple moving average is $23.12 and its two-hundred day simple moving average is $25.07. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The firm has a market cap of $133.38 billion, a PE ratio of 16.64, a price-to-earnings-growth ratio of 0.64 and a beta of 0.58.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. During the same period in the previous year, the firm posted $0.82 EPS. The company's quarterly revenue was down 7.8% compared to the same quarter last year. On average, equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 annualized dividend and a dividend yield of 7.33%. Pfizer's dividend payout ratio is currently 124.64%.

Analyst Ratings Changes

A number of brokerages have weighed in on PFE. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. UBS Group lifted their price objective on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. Finally, The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.